Chinese authorities have issued guidelines recommending Roche’s anti-inflammation drug Actemra to combat severe complications caused by the COVID-19 coronavirus.
There has been a political dimension to the coronavirus outbreak – there were the accusations of a cover-up by Chinese authorities around its epicentre in Wuhan – and in the
China’s BrightGene Bio-Medical Technology has been censured by the Shanghai Stock Exchange for wrongly claiming it is able to manufacture Gilead’s experimental drug remdesivir – scientists’
